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A pharmaco-economic study of the administration ofadjunctive therapy in patients with chronic epilepsy is 
described. A decision-analytic model has been used, which represents he consequences of treatment over a 1- 
year time period, when one of three drugs is used first. The cost-effectiveness ratio for clobazam, lamotrigine 
and vigabatrin have been calculated. 
The expected cost per patient of treatment over the 1-year period was up to 50% higher with vigabatrin and 
lamotrigine compared with clobazam, with a cost-effectiveness ratio around 40c/c higher. 
Key words: pharmaco-economics; epilepsy, clobazam; lamotrigine; vigabatrin. 
INTRODUCTION 
Ever-increasing demand for healthcare ser- 
vices in an environment of limited resource 
availability has become a key issue facing the 
National Health Service. An ageing popu- 
lation, technological dvance and rising public 
expectations with respect o healthcare have 
all fuelled the demand for funding and brought 
efficiency in resource use to the top of the 
health service agenda. 
In long-term chronic conditions in particu- 
lar, clinicians and health service managers 
alike are increasingly seeking out the most 
cost-effective form of treatment, hus ensuring 
maximum outcome from limited budgets. 
This paper is concerned with epilepsy and an 
assessment of the most cost-effective use of 
alternative adjunctive anticonvulsants. Thus, 
although it seems clear that the majority of 
patients can be adequately treated with a 
single anticonvulsant, in well-tailored mono- 
therapy, for a significant minority additional 
medications are required. Until recently there 
were few alternative strategies for use after 
the more standard anticonvulsants had been 
tried, alone or in combination. In recent years, 
several newer drugs have become available, 
and are at present recommended only for use 
as polytherapy, being added to an existing 
anticonvulsant regimen. 
Clobazam, a 1,5-benzodiazepine, was one of 
the first drugs indicated for such use, and the 
term adjunctive therapy was introduced 1.This 
has now been followed in the UK by vigaba- 
trin, lamotrigine and gabapentin. The term 
rational polytherapy is becoming fashionable. 
The introduction of these drugs has substan- 
tial cost implications for the management of 
epilepsy. Of these compounds, clobazam is sub- 
stantially lower priced than the rest, but its 
use as first line adjunctive therapy has been 
limited by the development of tolerance in a 
proportion of patients in whom it initially 
achieves good control 2. At the same time, a 
number of patients do retain their initial re- 
sponse to clobazam and are satisfactorily 
treated over the long-term 3.
The present study considers the economic 
consequences of prescription of adjunctive anti- 
convulsant therapies. A decision-analytic 
model has been developed to represent he 
consequences of treatment with three drugs as 
adjuvant therapy in epilepsy over a 1-year 
time period. The model was used to estimate 
the expected cost per patient of treatment and 
the overall proportion of successfully treated 
patients after 1 year, for each of three treat- 
ment alternatives: starting patients on 
clobazam or vigabatrin or lamotrigine. The 
'cost per successfully treated patient', or cost- 
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Fig. 1 : Model of treatment consequences over one year for adjunctive drug therapy in intractable pilepsy. 
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effectiveness ratio, was calculated for each 
drug. 
METHODS 
Method of treatment consequences 
A model of treatment consequences for adjunc- 
tive therapy in epilepsy was developed to esti- 
mate the expected cost per patient of treatment 
and the proportion of successfully treated 
patients for each of the three alternatives 
(starting patients on either clobazam, vigaba- 
trin or lamotrigine). A treatment period of 1 
year was assessed, as this was considered long 
enough for tolerance to develop in the majority 
of patients if it was going to do so 1 and for the 
long-term effects of therapy to be examined. 
The model was developed based on clinical 
experience with the drugs and a review of rel- 
evant literature, and is best explained with 
reference to Fig. 1. 
Seizure 'control' at any point was defined as 
having at least a 50% reduction in seizure fre- 
quency relative to pre-treatment levels. For 
patients receiving clobazam, initial control 
could be lost at 3, 6, 9 or 12 months, depending 
on whether or not tolerance developed. By con- 
trast, for patients treated with vigabatrin or 
lamotrigine, it was assumed that initial 
control at 3 months was retained over the long- 
term, with no drop-out due to tolerance (the 
implications of this are discussed later). 
At any point where a patient was not con- 
trolled, treatment was switched to another 
therapy, as would be the case in normal clini- 
cal practice. Patients initially on clobazam 
were switched to vigabatrin in the event of fail- 
ure, and subsequently to lamotrigine if a sec- 
ond failure occurred. For patients treated 
initially with vigabatrin, lamotrigine was 
given if treatment failed, followed by cloba- 
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zam, and for those treated initially with lamo- 
trigine, vigabatrin was given, then clobazam. 
When a third failure occurred, a fourth new 
adjunctive therapy, gabapentin, was adminis- 
tered. 
A patient was defined as a treatment success 
if they met two specific criteria: 
Long-term seizure control (of at least a 50% 
reduction in seizures) was achieved by the 
end of the 12-month treatment period. (In 
the case of patients on clobazam, control 
must have been maintained for a mini- 
mum of 12 months before it could be 
defined as 'long-term' due to the possible 
development oftolerance at any time up to 
that point; for vigabatrin and lamotrigine, 
3 months only was sufficient.) 
At the same time, control must have been 
achieved for a minimum of 9 months out of 
12 during the treatment period itself. 
(Without this criteria, a patient may have 
been uncontrolled for too long during the 
initial 12 months to be considered success- 
fully treated, even if results were later 
achieved.) 
These two criteria, associated with routes 1, 
3, 5 and 8 in the model, reflected as fully as 
possible the definition of 'successful treatment' 
considered most relevant to the 'real world' 
situation. By estimating the proportion of 
patients following these four routes for each of 
the three drugs, an overall percentage of suc- 
cessfully treated patients could be obtained in 
each case. 
The expected cost per patient of treatment 
for each drug was calculated by summing the 
estimated costs of all twelve routes through the 
model, weighted by the proportion of patients 
expected to follow them. 
Cost data 
Cost data incorporated into the model included 
the cost of any drug treatment given, both 
initially and if treatment was switched, and 
the cost of extra clinic visits, should a patient 
not be controlled on their current therapy. It 
was assumed that the costs of treating side- 
effects and of any necessary blood monitoring 
activity were equivalent for each of the three 
drugs and did not therefore need to be included 
in the analysis. The implications of this as- 
sumption are addressed later. 
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Recommended rug dosage regimens and 
unit drug costs for clobazam, vigabatrin, lamo- 
trigine and gabapentin were obtained from the 
Monthly Index of Medical Specialities (MIMS), 
October 1993 a. Dosage regimens used in clini- 
cal practice, where these differed from the 
doses recommended in MIMS, were obtained 
from personal preference, and discussion with 
colleagues. 
The unit cost of a clinic visit was estimated 
from the cost of an outpatient attendance pub- 
lished by the Department of Health in 19904 , 
inflated to 1993 prices ~'s. The expected number 
of extra clinic visits incurred when a patient 
was not controlled was calculatd from our own 
clinical experience. 
Clinical data 
Clinical data incorporated into the model 
included efficacy rates for clobazam at 3, 6, 9 
and 12 months, and for vigabatrin and lamotri- 
gine at 3 months only (it has been assumed 
there was no long-term drop-out with the 
newer drugs}. Efficacy rates were required in 
terms of the proportion of patients achieving at 
least a 50% reduction in seizures relative to 
baseline. 
Data for vigabatrin were obtained from a 
review published in 19937, which included a 
summary of all short-term trials completed on 
the drug up to that time. An average and maxi- 
mum/minimum values were obtained from the 
three 3-month trials within the review, and the 
average used as the 'basecase' fficacy value for 
vigabatrin. 
Rates for lamotrigine were obtained from a 
review published in 1991 s, which included a 
summary of four single-centre controlled 
trials, one multi-centre controlled trial and 27 
open studies involving lamotrigine, all of 
which had a treatment period of approximately 
3 months. Again, an average and maximum/ 
minimum values were calculated from these 
three sources of data, with the average used as 
the basecase fficacy value. 
Efficacy rates for clobazam were obtained 
from the only two trials apparent in the litera- 
ture a, lo which provided data on the proportion 
of patients with a 50% reduction in seizures at 
3, 6, 9 and 12 months. In selecting these trials, 
all studies in the 1986 review of clobazam by 
Robertson I were considered, as were later 
publications by Heller, Buchanan and 
Guberman 11-1a. Only the studies by Allen in 
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Table 1 : Range of dosage regimens and drug costs for clobazam, vigabatrin and lamotrigine 
B.A. O'Neill et aL 
Source Dosage regimen 
Drug costs (£) 
3 months 6 months 9months  12 months 
Clobazam 
Vigabatrin 
Lamotrigine 
Basic MIMS, 
recommended dose ( 3 I 
Maximum MIMS 
recommended dose (3) 
Dose recommended by
epilepsy specialist (2) 
Basic MIMS, 
recommended dose (3) 
Dose recommended by 
epilepsy specialist (2) 
Basic MIMS 
recommended dose (3) 
MIMS recommended 
dose if used with 
valproate (3) 
Dose recommended by 
epilepsy specialist (2) 
30 mg daily 
60 mg daily 
10 mg dai ly--2 weeks 
20 mg dai ly- -maintenance 
2 g dai ly--2 weeks 
3 g dai ly--maintenance 
0.5 g- -  1 week 
lg  - -1 week 
1.5 g--1 week 
2g - -maintenance 
50 mg b.d.--2 weeks 
100 mg b.d.--2 weeks 
150 mg b.d.--maintenance 
25 mg b.d.--2 weeks 
50 mg b.d.--2 weeks 
75 mg b.d.--maintenance 
As per MIMS recommended 
dose 
36.01 72.02 108.03 144.04 
72.02 144.04 216.06 288.08 
22.19 46.24 70.29 94.34 
238.28 489.44 740.60 991.76 
148.12 315.56 483.00 650.44 
244.64 533.76 822.88 1112.00 
142.56 311.04 479.52 648.00 
19859 and by the Canadian Clobazam Cooper- 
ative Group in 1991 l° provided the necessary 
data in the form required for the analysis. In 
practice, the two chosen trials covered a wide 
time period, from as early as 1985 to as recent 
as 1991, and involved as few as 52 patients to 
as many as 877. Again, average, maximum 
and minimum values were taken, with the 
averages used as basecase values for clobazam. 
Three month efficacy rates for the fourth 
drug, gabapentin, were also required for the 
model. A summary figure for the proportion of 
patients achieving a 50% or more reduction in 
seizures on gabapentin was obtained from a 
short review of new adjunctive anticonvulsants 
published in 1993.14 
Cost-effectiveness ratios 
The expected cost per patient of treatment and 
the overall proportion of successfully treated 
patients after 1 year's therapy for each of the 
three alternatives were obtained from the com- 
pleted model and used to calculate a cost- 
effectiveness ratio (CER) in each case, using 
the formula below; 
CER = Cost per successfully treated patient = 
Expected cost per patient of treatment 
% of successfully treated patients 
The treatment alternative with the lowest 
cost-effectiveness ratio effectively represents 
optimal value for money. 
A number of sensitivity analyses were 
carried out to test the robustness of the model. 
Variables tested included efficacy rates for all 
three drugs, their dosage regimens (and thus 
drug costs}, and the number of extra clinic 
visits incurred if a patient was not controlled 
on their current reatment. 
RESULTS 
Cost data 
The range of dosage regimens and associated 
drug costs obtained in the analysis is outlined 
in Table 1. Based on the doses recommended in 
MIMS (i.e. the basecase situation}, drug costs 
for vigabatrin and lamotrigine were approxi- 
mately seven to eight times higher than those 
for clobazam, with lamotrigine slightly more 
expensive than vigabatrin. The costs of lamo- 
trigine were greatly reduced if it was to be used 
in conjunction with valproate, thus requiring 
the dose to be halved. It was still, however, 
more than four times as expensive as clobazam 
and, in clinical practice, would also require 
regular blood monitoring to be conducted when 
used with valproate, thus raising the cost once 
again. 
The dosage regimens used in clinical prac- 
tice differ from those recommended in MIMS 
for clobazam and vigabatrin, and were more 
conservative in both cases, thus lowering the 
basic drug cost. 
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Table 2: Clinical efficacy of clobazam, vigabatrin and lamotrigine at relevant ime periods 
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q of  pat ients  cont ro l led*  
Drug  S i tuat ion  3 months  6 months  9 months  12 months  References  
C lobazam Basecase  35 24 21 21 
Max imum 40 39 37 36  i9, 10) 
M in imum 29 10 6 6 
V igabat r in  Basecase  45 - -  - -  - -  
Max imum 52 - -  - -  - -  (7) 
M in imum 33 - -  - -  - -  
Lamotr ig ine  Basecase  26 - -  - -  - -  
Max imum 30 - -  - -  - -  ~8) 
M in imum 20 - -  - -  - -  
* 'Cont ro l led '  is de f ined  as  hav ing  a t  leas t  50c~ reduct ion  in se izure  f requency  compared  w i th  base l ine .  
Table 3: Cost-effectiveness ratios for clobazam, vigabatrin and lamotrigine--basecase 
Drug Expected  cost  per  ~;~ of  success fu l ly  t reated  Cost -e f fec t iveness  ra t io  (£) Re la t ive  cost-  
pat ient  of  t reatment  ~£) pat ients  Iq  ) (cost per  success fu l ly  e f fec t iveness  vs 
t reated  pat ient )  c lobazam 
C lobazam 584.89  56.6  1034 - -  
V igabat r in  858 .05  59.3 1447 1.40:1 
Lamotr ig ine  877.22  59.3 1479 1.43:1 
In addition, the cost of the fourth medicine, 
gabapentin, was calculated at £165.10 for 3 
months treatment :~,the maximum time for 
which it was administered in the model. 
The unit cost of an extra clinic visit, required 
if seizures were not controlled, was calculated 
at £40.004-6. It was considered that, in normal 
circumstances, no extra clinic visits would be 
incurred as a result of poor control of a 
patient's epilepsy, since the majority of 
patients would be already attending clinics on 
a regular basis, probably at least as often as 
once every 3 months and particularly after 
starting a new drug. Therefore, in the basecase 
situation, no additional clinic visits were 
included in the analysis. However, one extra 
clinic visit per 3-month period in which a 
patient was not controlled, was incorporated 
into the sensitivity analysis. 
Clinical data 
The efficacy rates for clobazam, vigabatrin and 
lamotrigine used in the analysis are outlined 
in Table 2. In each case, basecase, maximum 
and minimum values are given for the percent- 
age of patients controlled on each drug at the 
relevant ime periods. Initial 3-month efficacy 
rates were highest with vigabatrin (45% of 
patients with at least a 50% reduction in seiz- 
ures) and lowest with lamotrigine (26% of 
patients meeting the same criteria). However, 
the longer-term drop-out with clobazam over 
time resulted in a final basecase fficacy rate 
for clobazam of 21% at 12 months. 
The basic 3-month efficacy rate for gabapen- 
tin was 42c/c ~4. 
Cost-effectiveness ratios 
By inputting the cost and clinical data into the 
model, the expected cost per patient of treat- 
ment and the overall proportion of successfully 
treated patients were obtained for each of the 
three comparators and used to calculate the 
cost per successfully treated patient, or cost- 
effectiveness ratio, in each case {Table 3). 
The expected cost per patient of treatment 
over the 1-year period was up to 50% higher 
when patients were started on vigabatrin 
{£858) or lamotrigine (£877) rather than on clo- 
bazam (£584). However, only 2.7% more 
patients would be successfully treated at the 
end of the 12 months when started with the 
newer drugs. As a result, the cost per success- 
fully treated patient, or cost-effectiveness 
ratio, for the vigabatrin and lamotrigine 
options was around 40% higher than for cloba- 
zam. 
The strength of this result was tested using 
several sensitivity analyses, the findings of 
which are presented in Table 4. When a 
number of key variables were changed in the 
model in order to favour vigabatrin and lamo- 
trigine (conditions 1-5, Table 4), the cost- 
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Table 4: Relative cost-effectiveness vs clobazam--sensitivity analysis 
B.A. O'Neill et aL 
Additional conditions considered 
Relative cost-effectiveness vs 
clobazam 
Vigabatrin Lamotrigine 
1. One extra clinic visit per 3 month period when a patient was not controlled 1.34:1 
2. Minimum efficacy clobazam 1.07:1 
3. Maximum efficacy vigabatrin/lamotrigine 1.40:1 
4. Maximum dose clobazam 1.29:1 
5. Minimum doses vigabatrin-lamotrigine* 1.32:1 
6. 'Worst case' scenario 1:1.10 
- -  Extra clinic visit, minimum efficacy clobazam, maximum dose clobazam, 
minimum dose vigabatrin/lamotrigine 
7. 'Best case' scenario 1.89:1 
- -  No extra clinic visit, maximum efficacy clobazam, minimum dose clobazam+, 
maximum dose vigabatrin/lamotrigine 
1.38:1 
1.09:1 
1.44:1 
1.32:1 
1.31:1 
1:1.10 
1.93:1 
* Dose recommended by epilepsy specialist for vigabatrin, half dose lamotrigine lassumed with valproatel. 
t Dose recommended byepilepsy specialist for clobazam. 
effectiveness advantage for clobazam, though 
reduced to varying degrees, was still retained. 
A 'worst case' scenario was then tested Icon- 
dition 6, Table 4) in which all of the conditions 
1-5 were imposed simultaneously twith the 
exception of number 3 which had no impact on 
relative cost-effectiveness*). In this case, the 
result altered to favour the newer drugs, 
although the magnitude of the cost-effective- 
ness advantage was small {around 10ok}. 
When the opposing situation was tested, 
with all variables changed to favour clobazam 
(condition 7, Table 4), the 1,5-benzodiazepine 
became almost twice as cost-effective as viga- 
batrin or lamotrigine. 
DISCUSSION 
A number of points should be highlighted 
before suggesting that the study findings may 
be used as a basis for decision-making. 
First, we have not assessed the direct cost- 
effectiveness of clobazam, vigabatrin and 
lamotrigine. The present study considers the 
cost-effectiveness of starting patients on each 
treatment, with subsequent changes in ther- 
apy if necessary. Thus the complete treatment 
package is taken into consideration, not just 
the effects of initial therapy. So, for example, a
* In the event of maximizing the efficacy of vigabatrin and 
lamotrigine (case 4 in Table 4), there was no change in rela- 
tive cost-effectiveness compared with the basecase situation. 
The reason for this was that, in maximizing the efficacy of 
vigabatrin and lamotrigine in the model, overall drug costs 
were also increased, as more patients continued to receive 
the newer drugs during the treatment period. This negated 
any advantage gained in relative cost-effectiveness due to the 
improvement in efficacy. 
patient not controlled after 3 months on cloba- 
zam who subsequently achieves long-term 
control with vigabatrin is classified as a treat- 
ment success for the clobazam group. Equally, 
a patient initially uncontrolled on vigabatrin 
but later successful on lamotrigine, can be 
defined as a success for the vigabatrin alterna- 
tive. This approach is adopted as the most rel- 
evant to the 'real world' situation, but must 
nonetheless be borne in mind in interpreting 
the study findings. We accept he fact that our 
comparisons are based on the outcomes of pub- 
lished clinical trials, which may not ultimately 
reflect clinical practice. However, the data are 
in the public domain, and must represent the 
best available source of our information about 
the new drugs. We are currently applying the 
model described above to clinical practice. 
However, in the meantime the figures we have 
arrived at are based on pharmaco-economic 
principles, of the sort that are more and more 
being employed in evaluating health care and 
its delivery. 
The chosen definition of treatment success is 
also significant, as changes in this definition 
are likely to affect the results. For example, if 
the level of control required in the study was 
changed from a 50% reduction in seizure fre- 
quency to the complete radication of seizures, 
then the result would be different, probably 
acting in this case to further support clobazam 
and vigabatrin since a relatively high pro- 
portion of patients are seizure-free when 
treated with these agents 1'7' s. is. By contrast, if 
only patients controlled for 12 months during 
the initial treatment period were to be defined 
as treatment successes (i.e. not permitting 3 
months without control early on in the course 
of achieving long-term success), then the 
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results would more likely favour vigabatrin 
and lamotrigine. 
In addition, two assumptions have been 
made which may have also influenced the 
study outcome. First, it was assumed that, once 
controlled on either vigabatrin or lamotrigine, 
patients retained that control for the remain- 
der of the treatment period, with no long-term 
drop-out due to tolerance. This assumption 
may have favoured vigabatrin and lamotrigine 
in the analysis by overestimating their long- 
term effectiveness (in practice, there is some 
evidence of withdrawal from these drugs, cer- 
tainly in the case of vigabatrinT). As a result, it 
is possible that the cost-effectiveness advan- 
tage demonstrated for clobazam in the study 
has been under-represented. 
The second assumption, which may have 
also under-estimated the cost-effectiveness of 
clobazam, was the omission of the costs of blood 
monitoring and treating side-effects from the 
model, on th~ ~rounds that they were approxi- 
mately equivalent for all three drugs. Again, 
there is evidence to suggest hat these two 
sources of cost are in fact higher for vigabatrin 
and lamotrigine: blood monitoring is more 
likely to be required with the newer drugs due 
to the greater isk of drug interactions 1"2'v'~6 
while side-effects can be more severe and thus 
most costly in a small proportion of patients on 
vigabatrin and lamotrigine (due to behaviour 
change and rash, respectively) 2' v. is, 16. 
Within these constraints, however, con- 
clusions can still be drawn from the analysis. 
There appears to be a clear cost-effectiveness 
advantage demonstrated for clobazam over 
vigabatrin and lamotrigine. In clinical terms, 
when adjunctive therapy is required, this is the 
most cost effective drug of the three to begin 
treatment with. What this means in practice is 
that it costs substantially ess to achieve suc- 
cessful treatment after 1 year when patients 
are started on clobazam rather than on vigaba- 
trin or lamotrigine. 
In a situation of limited budgets, more 
patients are successfully treated using cloba- 
zam as the first choice adjunctive drug rather 
than vigabatrin or lamotrigine. For example, if
an epilepsy clinic had an annual budget of 
£50 000 for adjunctive therapy, then, based on 
the results in Table 3, around 48 patients can 
be successfully treated using clobazam first 
(£1034 per successfully treated patient) com- 
pared with only 33 or 34 patients if lamotrigine 
or vigabatrin are the first choice drugs (£1479 
and £1447 per success, respectively). 
Even when budgets are not fixed, the study 
results still strongly favour the use of cloba- 
zam. If, for example, 50 patients are treated at 
an epilepsy clinic over the course of 1 year, 
then the total expected cost of treatment is 
around £29000 when clobazam is used first 
(derived from Table 3), compared with £43- 
44000 for the vigabatrin or lamotrigine 
alternatives. Despite this extra £14-15 000 of 
expenditure, however, only one additional 
patient is successfully treated using the newer 
drugs (29 successfully treated patients for 
vigabatrin or lamotrigine vs 28 for clobazam). 
Additional analysis is recommended ither to 
develop the present study further (e.g. incor- 
porating side-effects and blood monitoring 
costs into the analysis) or to address other cost- 
effectiveness i sues in the field of epilepsy, 
such as the value for money of surgical inter- 
vention or vocational rehabilitation pro- 
grammes. Quality of life determination should 
also be incorporated into such models. Either 
way, the need to examine the most efficiant use 
of resources is long-term chronic conditions 
such as epilepsy is likely to become increas- 
ingly significant in future years. 
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